Evotec AG has reached a milestone in its research alliance with Boehringer Ingelheim, triggering a 4.0 million euro payment for the transition of an oncology molecule into preclinical development.   Dr. Mario Polywka, chief operating officer of Evotec said, “This is the 21st milestone achieved as part of our alliance with Boehringer Ingelheim and represents a third oncology compound transitioning into preclinical development of which one is already in Phase I clinical trials. Our collabora...